Gilead Sciences, Inc. $GILD Shares Acquired by Range Financial Group LLC

Range Financial Group LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 182.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,330 shares of the biopharmaceutical company’s stock after buying an additional 4,087 shares during the quarter. Range Financial Group LLC’s holdings in Gilead Sciences were worth $943,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Persistent Asset Partners Ltd bought a new stake in shares of Gilead Sciences in the second quarter valued at about $25,000. Kimelman & Baird LLC purchased a new stake in Gilead Sciences in the second quarter worth about $25,000. Wiser Advisor Group LLC purchased a new stake in Gilead Sciences in the second quarter worth about $30,000. Wilkerson Advisory Group LLC grew its holdings in Gilead Sciences by 54.2% during the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 78 shares in the last quarter. Finally, Toth Financial Advisory Corp grew its holdings in Gilead Sciences by 85.5% during the 3rd quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 100 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $156.51 on Wednesday. The company has a market capitalization of $194.06 billion, a PE ratio of -58.62 and a beta of 0.31. The company has a 50-day simple moving average of $148.01 and a two-hundred day simple moving average of $137.50. Gilead Sciences, Inc. has a one year low of $114.02 and a one year high of $160.51. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. During the same period last year, the business earned $2.01 EPS. The company’s revenue was up 10.6% compared to the same quarter last year. Research analysts expect that Gilead Sciences, Inc. will post -0.47 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were given a dividend of $0.82 per share. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.1%. Gilead Sciences’s dividend payout ratio is presently -122.85%.

Analysts Set New Price Targets

A number of research analysts have commented on GILD shares. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $160.00 to $170.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $123.00 to $126.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 8th. Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Finally, Needham & Company LLC reissued a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a report on Wednesday, August 5th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $159.63.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the sale, the insider directly owned 113,684 shares in the company, valued at $17,759,714.48. This trade represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the sale, the director owned 10,066 shares of the company’s stock, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 111,000 shares of company stock valued at $15,877,860 over the last three months. Company insiders own 0.30% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Ulcerative colitis trial success strengthens the pipeline. Gilead reported positive Phase 2 SWIFT results for emvistegrast, an oral treatment for active ulcerative colitis. The data were described as “highly competitive,” supporting management’s strategy to expand into immunology and inflammatory bowel disease. Success in a large market could diversify Gilead beyond its HIV franchise. Gilead’s highly competitive mid-stage ulcerative colitis data validate I&I push
• Positive Sentiment: Bank of America raised its price target and maintained a Buy rating. The target increased from $168 to $172, implying roughly 10% upside from the referenced price and signaling confidence in Gilead’s earnings outlook and pipeline prospects.
• Positive Sentiment: Recent FDA decisions add commercial catalysts. Gilead received approval for the Bixlenvo HIV regimen, a first-line label expansion for Trodelvy in metastatic triple-negative breast cancer, and approval for Hepcludex in chronic hepatitis delta. The company will also present 28 HIV and antiviral research findings at IDWeek 2026, potentially providing additional clinical updates. How Investors Are Reacting To Gilead Sciences FDA Drug Approvals
• Positive Sentiment: Analyst and quantitative sentiment improved. Gilead was upgraded to Zacks Rank #2 (Buy), reflecting improving expectations for earnings prospects. Separately, 43 ETFs added Gilead shares, indicating some institutional demand. Gilead rating upgrade to Buy
• Neutral Sentiment: Investors are weighing acquisitions against Gilead’s dependable HIV cash flow. Biktarvy and other HIV products continue to support recurring revenue and the dividend, but acquisitions such as Arcellx and Tubulis have increased research and integration costs. Gilead reportedly recorded a substantial trailing loss as it absorbs those investments.
• Negative Sentiment: ETF selling and near-term profitability concerns could limit gains. ETFs were also reported as net sellers of Gilead on October 16, while coverage noted that the ulcerative-colitis trial win initially failed to lift the stock. Investors may remain focused on acquisition-related expenses and the path back to sustainable positive earnings. ETFs Are Net Sellers of Gilead Sciences

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.